| References |
| 1 |
Cerner Multum, Inc. "UK Summary of Product Characteristics.".
|
| 2 |
Fang AF, Damle BD, Labadie RR, Crownover PH, Hewlett D, Glue PW "Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects." Pharmacotherapy 28 (2008): 42-50. [PMID: 18154473]
|
| 3 |
Product Information. Viracept (nelfinavir). Agouron Pharma Inc, La Jolla, CA.
|
| 4 |
Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
|